12/04/2019 18:00:00

Invitation to Northrop Grumman’s First Quarter 2019 Financial Results Conference Call

FALLS CHURCH, Va., April 12, 2019 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) plans to release its first quarter 2019 financial results on Wednesday, April 24, 2019. You are invited to participate in a conference call following this release. The information is:

Date:Wednesday, April 24, 2019
  
Time:Noon Eastern time, 9 a.m. Pacific time
 Call in by 11:45 a.m. Eastern time, 8:45 a.m. Pacific time
  
Call-in Number:1-877-693-0268 – domestic
 1-409-216-0444 – international

A live audio broadcast of the conference call will be available on the Investor Relations page of the Northrop Grumman website at https://www.northropgrumman.com.

For those who cannot participate in this call, it will be archived on the Investor Relations page for a limited time. It will also be recorded and available through Wednesday, May 1, 2019, by calling 1-855-859-2056 (domestic) or 1-404-537-3406 (international).  Please use conference ID 5622389.

If you have any questions, please call Steve Movius, vice president, Investor Relations, at 703-280-4575 or Denny McSweeny, director, Investor Relations at 703-280-4578.

Primary Logo

Related content
11 Jul - 
Invitation to Northrop Grumman’s Second Quarter 2019 Fi..
10 Jul - 
Northrop Grumman Announces Webcast, Conference Call of ..
09 Jul - 
Northrop Grumman Board Names Kathy J. Warden Chairman
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
uBreakiFix Expands Dallas Footprint With Grand Prairie Store
2
REVLON 24 HOUR DEADLINE ALERT: APPROXIMATELY 24 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Revlon, Inc. - REV
3
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
4
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
5
Aemetis India Expands Revenues to $50 Million Per Year Run Rate Driven by Biodiesel Shipments to Large Refiners

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2019 01:53:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB1 - 2019-07-16 02:53:41 - 2019-07-16 01:53:41 - 1000 - Website: OKAY